Summary
AIDPATH (Artificial Intelligence-driven, Decentralized Production for Advanced Thera-pies in the Hospital) is a high-energy EU consortium, dedicated to enable and to augment the next-generation of personalized medicine at EU hospitals through the use of AI tech-nology. The exemplary embodiment of gene-engineered immune cells in AIDPATH will be T cells expressing a synthetic chimeric antigen receptor (CAR-T). These cells are already a revolutionary novel treatment in hematology and oncology, and will also be useful for treating infections and autoimmune diseases. Conventional CAR-T therapy is complicated by complex logistics from centralized manufacturing facilities, inflexible manufacturing and clinical use schemes that disregard patient and cell characteristics, thus limiting patient access and therapeutic outcome.
AIDPATH will apply top-notch AI technology to integrate patient-specific data and biomarkers in CAR-T therapy, and apply flexible manufacturing schemes to obtain CAR-T cell products with optimal fitness and anti-tumor potency. AI technology will be applied in pre- and in-process controls to reduce cost and hospital resource utilization and to augment patient access. AIDPATH will establish a role model that integrates the hospital in a smart manner, incorporating aspects of logistics, capacity planning, data management and cybersecurity by design. The project is designed to enable smart ‘bedside’ provision of personalized treatments and to accomplish end-to-end automation of hospital-based CAR-T manufacture. A key deliverable in AIDPATH will be an integrated cyberphysical infrastructure for rapid dissemination of the ‘smart CAR-T manufacturing and clinical use’ concept to hospitals throughout the EU.
AIDPATH brings together a world-class consortium to address these challenges, consisting of key opinion leaders in science and translational medicine, innovative SMEs and commercial partners, patient advocates, policy makers and regulatory experts.
AIDPATH will apply top-notch AI technology to integrate patient-specific data and biomarkers in CAR-T therapy, and apply flexible manufacturing schemes to obtain CAR-T cell products with optimal fitness and anti-tumor potency. AI technology will be applied in pre- and in-process controls to reduce cost and hospital resource utilization and to augment patient access. AIDPATH will establish a role model that integrates the hospital in a smart manner, incorporating aspects of logistics, capacity planning, data management and cybersecurity by design. The project is designed to enable smart ‘bedside’ provision of personalized treatments and to accomplish end-to-end automation of hospital-based CAR-T manufacture. A key deliverable in AIDPATH will be an integrated cyberphysical infrastructure for rapid dissemination of the ‘smart CAR-T manufacturing and clinical use’ concept to hospitals throughout the EU.
AIDPATH brings together a world-class consortium to address these challenges, consisting of key opinion leaders in science and translational medicine, innovative SMEs and commercial partners, patient advocates, policy makers and regulatory experts.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101016909 |
| Start date: | 01-01-2021 |
| End date: | 31-12-2024 |
| Total budget - Public funding: | 10 964 007,00 Euro - 9 860 991,00 Euro |
Cordis data
Original description
AIDPATH (Artificial Intelligence-driven, Decentralized Production for Advanced Thera-pies in the Hospital) is a high-energy EU consortium, dedicated to enable and to augment the next-generation of personalized medicine at EU hospitals through the use of AI tech-nology. The exemplary embodiment of gene-engineered immune cells in AIDPATH will be T cells expressing a synthetic chimeric antigen receptor (CAR-T). These cells are already a revolutionary novel treatment in hematology and oncology, and will also be useful for treating infections and autoimmune diseases. Conventional CAR-T therapy is complicated by complex logistics from centralized manufacturing facilities, inflexible manufacturing and clinical use schemes that disregard patient and cell characteristics, thus limiting patient access and therapeutic outcome.AIDPATH will apply top-notch AI technology to integrate patient-specific data and biomarkers in CAR-T therapy, and apply flexible manufacturing schemes to obtain CAR-T cell products with optimal fitness and anti-tumor potency. AI technology will be applied in pre- and in-process controls to reduce cost and hospital resource utilization and to augment patient access. AIDPATH will establish a role model that integrates the hospital in a smart manner, incorporating aspects of logistics, capacity planning, data management and cybersecurity by design. The project is designed to enable smart ‘bedside’ provision of personalized treatments and to accomplish end-to-end automation of hospital-based CAR-T manufacture. A key deliverable in AIDPATH will be an integrated cyberphysical infrastructure for rapid dissemination of the ‘smart CAR-T manufacturing and clinical use’ concept to hospitals throughout the EU.
AIDPATH brings together a world-class consortium to address these challenges, consisting of key opinion leaders in science and translational medicine, innovative SMEs and commercial partners, patient advocates, policy makers and regulatory experts.
Status
SIGNEDCall topic
DT-ICT-12-2020Update Date
26-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Search
Organisations
-
| FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (Coördinator)
-
| AGLARIS CELL SL
-
| AGLARIS LIMITED
-
| FUJIFILM EUROPE BV
-
| FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA
-
| HOSPITAL CLINIC DE BARCELONA
-
| IDRYMA TECHNOLOGIAS KAI EREVNAS
-
| IRIS
-
| MTA SZTAKI
-
| ORTEC OPTIMIZATION TECHNOLOGY BV
-
| PANAXEA BV
-
| RED ALERT LABS
-
| SARTORIUS CELLGENIX GMBH
-
| UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT
-
| UNIVERSITY COLLEGE LONDON